Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GADOLIN: Obinutuzumab + Bendamustine in Rituximab-Refractory iNHL
NCT01059630Phase 3Completed
- Sponsor
- Genentech
- Start
- Apr 2010
- Primary completion
- Sep 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab in Indolent Non-Hodgkin Lymphoma (INHL) (2 arms), sponsored by Genentech. Primary endpoints: Progression-Free Survival up to 4.5 years and Number of Participants With Progressive Disease or Death up to 4.5 years. Started Apr 2010; status: completed.
02
Drugs
obinutuzumab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT01059630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01059630.